IRBESARTAN, DAPAGLIFLOZIN, Sparsentan_DF3, Sparsentan_DF2
021IGAN17001
Phase 3 small_molecule active
Quick answer
IRBESARTAN, DAPAGLIFLOZIN, Sparsentan_DF3, Sparsentan_DF2 for Immunoglobulin A Nephropathy (IgAN) is a Phase 3 program (small_molecule) at Travere Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Travere Therapeutics
- Indication
- Immunoglobulin A Nephropathy (IgAN)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active